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It is now well established that patients with chronic
kidney disease have a heightened risk of cardiovascular
problems, probably not fully explained by conventional
risk factors [1–3]. Patients with end-stage renal failure
represent only the “tip of the iceberg” of individuals with
chronic kidney disease in the general population [1–5].
Reduction in the population burden of cardiovascular
events related to chronic kidney disease will require the
use of effective therapeutic interventions in those with
lesser degrees of renal impairment. Secondary preven-
tion represents a particularly effective strategy for reduc-
ing population burden. Absolute risk reduction is usually
large and cost-effectiveness high. As many patients with
established cardiovascular disease also have chronic kid-
ney disease and, as a consequence, are at particularly high
risk, it is valuable to examine the role of proven therapies
in relation to chronic kidney disease in these individuals.
The focus of this review is heart failure and coronary heart
disease, two of the most evidence-based therapeutic areas
in medicine.
HEART FAILURE
Heart failure is one of the most common cardiovas-
cular complications of end-stage renal failure. Chronic
kidney disease, however, is very common in patients with
heart failure (Table 1). The prevalence of chronic kid-
ney disease has been most clearly documented in patients
with a low left ventricular ejection fraction, usually par-
ticipating in clinical trials [6–12]. Although these trials
excluded patients with substantial elevations in serum
creatinine concentration, 30% to 40% of participants
had chronic kidney disease and, universally, chronic kid-
ney disease was associated with increased risk of an ad-
verse outcome [6–12]. Not surprisingly, cohorts of un-
selected patients admitted to hospital with decompen-
sated heart failure had an even higher prevalence (50%
to 70%) of chronic kidney disease, in part because of
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their older age [6–12]. Again, in these cohorts, renal func-
tion was a powerful independent predictor of outcome
[6–12].
Although patients with heart failure have a poor prog-
nosis (and those with heart failure and chronic kidney
disease a very poor prognosis), remarkable advances in
treatment have been made recently.
It is well known that angiotensin-converting enzyme
(ACE) inhibitors are the bedrock of treatment of low
left ventricular ejection fraction heart failure and these
agents will not be discussed further. It is useful, how-
ever, to recall that in the first mortality trials with an
agent in this class, the average age of patients was 70
years, the mean dose of furosemide was 224 mg/day, mean
serum creatinine 133 lmol/L and mean estimated crea-
tinine clearance 45 mL/min (using the Cockcroft-Gault
formula) [13, 14].
More recently, angiotensin receptor blockers have
been shown to be an effective alternative for patients
intolerant of an ACE inhibitor [15, 16]. In one trial, the
Candesartan in Heart failure: Assessment in Reduction
in Mortality and Morbidity (CHARM) Alternative, the
cause of ACE inhibitor intolerance was “renal dysfunc-
tion” in approximately 12% of patients [16]. Of those
patients, 12% in the placebo group and 23.1% in the can-
desartan group had to discontinue treatment because of
an increase in creatinine in the trial (compared to 2.7%
and 6.1% in the placebo and candesartan groups, respec-
tively, in the study overall).
In addition to an ACE inhibitor (or angiotensin recep-
tor blocker if ACE inhibitor not tolerated) there is now
compelling evidence that a beta blocker should be added.
Six large trials have now shown that the addition of a beta
blocker further reduces mortality, rapidly and substan-
tially, by the order of a third within 12 months [17–23].
In addition, these drugs reduce hospitalizations and im-
prove symptoms and quality of life [17–23]. As described
above, a substantial proportion of patients in those tri-
als had chronic kidney disease and one of them, the
second Cardiac Insufficiency Bisoprolol Study (CIBIS-
2), reported a retrospective analysis of outcomes ac-
cording to baseline renal function [24]. The benefits of
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Table 1. Renal function in major heart failure and myocardial infarction trials
Creatinine Mean/ Mean/ Mean/ Glomerular
Trial/ exclusion mediana mediana mediana glomerular filtration
number Test lmol/L age creatinine lmol/L filtration rate rate <60 mL/
of patients treatment (mg/dL) years (mg/dL) mL/min/1.73 m2 min/1.73 m2 (%)
Heart failure trials
CONSENSUS (243) [14] Enalapril >300 (3.4) 71 133 (1.5) 45b —
SOLVD (6630) [11] Enalapril >177 (2.0) 60 106 (1.2) 70.4 32
DIG (6800) [6] Digoxin >265 (3.0) 63 112 (1.27) 61.6a 46
CIBIS-2 (2647) [24] Bisoprolol ≥300 (3.4) 61 103 (1.17) 77.5b 33
COMET (3029) [21] Carvedilol vs. N/R 62 99a (1.12) 67.2 —
metoprolol
CHARM (2680) [26] Candesartan 265 (3.0) 66 97a (1.10) 69a 35
CARE-HF (813) [36] CRT N/R 66a 106a (1.20) 60a ∼50
Myocardial infarction trials
SAVE (2183) [59] Captopril ≥221 (2.5) 59 105 (1.2) 70.0 33
CARE (3384) [65] Pravastatin Creatinine >1.5 ULN 64 124 (1.4) 52.9 21
≥2+ proteinuria
VALIANT (14527) [42] Captopril ≥221 (2.5) 65 100 (1.1) 70.2 34
vs. valsartan
vs. combination
Abbreviations are: CONSENSUS, Cooperative North Scandinavian Enalapril Survival Study; SOLVD, Studies of Left Ventricular Dysfunction; DIG, Digitalis
Investigators Group; CIBIS-2, Second Cardiac Insufficiency Bisoprolol Study; COMET, Carvedilol Or Metoprolol European Trial; CHARM, Candesartan in Heart
Failure: Assessment in Reduction in Mortality and Morbidity; CARE-HF, Cardiac Resynchronization-Heart Failure; SAVE, Survival And Ventricular Enlargement;
CARE, Cholesterol And Recurrent Events; VALIANT, Valsartan in Acute Myocardial Infarction Trial; ULN, upper limit of local laboratory normal range; CRT,
cardiac resynchronization therapy.
bCreatinine clearance (mL/min) predicted from Cockcroft-Gault equation.
bisoprolol appeared to be preserved in patients with
an estimated glomerular filtration rate (eGFR) of <60
mL/min (and even in those with a GFR of <30 mL/min)
who were at much higher absolute risk than other pa-
tients. Thus, because the absolute risk was much higher
and the relative risk reduction with treatment preserved,
the absolute benefit of treatment in patients with chronic
kidney disease was large, which, as will become appar-
ent, is a common theme for most effective interven-
tions for cardiovascular disease in patients with chronic
kidney disease. Unfortunately, the renal effects of beta
blockade have not been well described in these recent
heart failure trials. The only information available if from
the Carvedilol Prospective Randomized Cumulative Sur-
vival trial (COPERNICUS) from which patients with a
serum creatinine concentration >248 lmol/L were ex-
cluded and in which the mean serum creatinine at base-
line was 134 lmol/L. “Abnormal renal function” (not de-
fined) was reported as a serious adverse event in 3.1% of
the placebo group and 1.9% of the carvedilol group (P =
0.069) [18, 19].
These major outcome trials are supported by a small
(N = 114) placebo-controlled trial with carvedilol specif-
ically in patients with dilated cardiomyopathy receiving
regular hemodialysis for end-stage renal disease (ESRD).
Left ventricular function improved with carvedilol com-
pared to placebo. The number of deaths in the placebo
group at 2 years was 41 (73%) compared to 30 (52%)
in the carvedilol group (P < 0.01). There were also sig-
nificantly fewer hospitalizations in the carvedilol group
[25].
The latest pharmacologic approach shown to be valu-
able in a broad spectrum of patients with low left ventric-
ular ejection fraction heart failure is the addition of an
angiotensin receptor blocker to both an ACE inhibitor
and beta blocker (this is different than substituting an
angiotensin receptor blocker in ACE inhibitor intoler-
ant patients). In the CHARM-Added trial, a large dose
(target 32 mg once daily) of candesartan reduced the
risk of cardiovascular death or heart failure hospital-
ization by 15% (P = 0.011) [26]. That additional bene-
fit was apparent even in patients taking a high dose of
ACE inhibitor. The median estimated GFR in CHARM-
Added was approximately 70 mL/min/1.73 m2 (33% had
an eGFR < 60 mL/min/1.73 m2). In the CHARM Pro-
gram, overall, the benefit of candesartan was compa-
rable in patients above and below the median eGFR
although patients with a markedly reduced eGFR were
substantially more likely to have to discontinue active
therapy.
In patients with severe heart failure, in the Randomized
Aldactone Evaluation Study (RALES), low dose (25 mg
daily) spironolactone reduced the risk of death from any
cause by 30% and reduced the risk of hospital admission
for cardiac reasons [27]. Patients with a serum creatinine
concentration >221 lmol/L were excluded from RALES
and the median creatinine concentration at baseline was
106 lmol/L. Although the risk of renal dysfunction and
hyperkalemia was low in that trial, there has been great
concern that these adverse effects were much more fre-
quent when spironolactone was used in “real world” pa-
tients [28, 29].
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Table 2. Effect of digoxin, compared to placebo, on outcomes in patients with heart failure, according to baseline renal function in the Digitalis
Investigators’ Group trial (DIG)
Mortality (digoxin vs. placebo) Hospitalizations/mortality (digoxin vs. placebo)
Adjusted HR P value Adjusted HR P value
(95% CI) for interaction (95% CI) for interaction
Estimated glomerular filtration
rate level mL/min/1.73 m2
>60 (N = 3643) 1.01 (0.89 to 1.14) 0.19 0.80 (0.72 to 0.88) 0.54
30 to 60 (N = 2939) 0.95 (0.85 to 1.07) 0.84 (0.76 to 0.93)
<30 (N = 218) 0.93 (0.65 to 1.35) 0.77 (0.55 to 1.08)
Creatinine concentration
(mg/dL)
≤1.0 (N = 1745) 1.15 (0.96 to 1.38) 0.06 0.92 (0.79 to 1.06) 0.12
1.1 to 1.5 (N = 3851) 0.94 (0.84 to 1.05) 0.78 (0.71 to 0.85)
1.6 to 2.0 (N = 915) 1.00 (0.83 to 1.21) 0.86 (0.72 to 1.01)
>2.0 (N = 289) 0.70 (0.51 to 0.97) 0.63 (0.47 to 0.84)
Adapted from [6].
African Americans are more likely to develop and die
from heart failure and there has been concern that they
may not obtain the same benefit from ACE inhibitors
as whites (although this interpretation has been contro-
versial) [30–32]. Because African-Americans appeared
to get a relatively greater benefit from the combination
of hydralazine and isosorbide dinitrate (H-ISDN) than
enalapril in the Second Vasodilator Heart Failure Trial
(V-HeFT II), a prospective placebo-controlled, random-
ized trial of H-ISDN was recently carried out in African
Americans [33]. The African American Heart Failure
Trial (A-HeFT) showed that H-ISDN, added to con-
ventional treatment (including an ACE inhibitor, beta
blocker, and spironolactone) reduced, significantly, the
primary composite end point and, also, the risk of death
and the rate of admission to hospital with worsening heart
failure. There was no specific renal-biochemical exclu-
sion from this study and baseline creatinine has not been
reported. At baseline, however, 17.2% of patients had
“renal dysfunction” (not defined). Baseline renal func-
tion did not modify the beneficial effects of H-ISDN. Al-
though the renal effects of H-ISDN are not described in
A-HeFT, the prior second V-HeFT trial showed reported
that serum creatinine increased more after 4 weeks and
1 year in the enalapril group than in the H-ISDN group
[34].
The role of digoxin as a treatment for patients with low
left ventricular ejection fraction heart failure and sinus
rhythm is now limited. Digoxin may improve symptoms
and reduce the risk of hospital admission for worsening
heart failure; these benefits may be more marked in pa-
tients with more advanced heart failure (higher New York
Heart Association class, lower left ventricular ejection
fraction, and larger heart on chest radiograph) [6, 35]. In
the Digitalis Investigators Group (DIG) trial, the effect
of digoxin was not modified by renal function although
dose adjustment is needed in patients with chronic kidney
disease (Table 2).
In addition to pharmacologic advances, device ther-
apy has been shown to improve outcome in low left ven-
tricular ejection fraction heart failure. In particular, atri-
obiventricular or multisite pacing, commonly referred
to as cardiac resynchronization therapy (CRT), in se-
lected patients, improved symptoms, functional capacity
and survival, and reduced hospital admissions [36–38].
Those very striking benefits were obtained in patients
receiving optimal pharmacologic treatment. So far, out-
come studies with CRT have only been conducted in pa-
tients with New York Heart Association class III and
IV symptoms and a wide QRS on their 12-lead ECG
(a marker of dys-synchrony) or echocardiographic ev-
idence of left ventricular dys-synchrony. Interestingly,
renal dysfunction has recently been shown to be associ-
ated with prolonged QRS duration in patients with heart
failure [39]. In the Cardiac Resynchronization in Heart
Failure Trial (CARE-HF), CRT was of equal benefit in
patients with an eGFR above and below the median of
60 mL/min/1.73 m2 (Table 1) [36, 37]. CRT necessitates
the passage of two electrodes into the right side of the
heart via a subclavian vein (usually left side) and su-
perior vena cava which may have implications for use
of dialysis and other indwelling catheters. An implanat-
ble cardioverter defibrillator (ICD) also reduces the risk
of death in patients with low left ventricular ejection
fraction heart failure (and a low left ventricular ejection
fraction after myocardial infarction) and devices that pro-
vide CRT and defibrillate (so called CRT-D) are available
[38, 40].
A high proportion of patients with heart failure may
have a preserved left ventricular ejection fraction, prob-
ably because they have diastolic dysfunction, for exam-
ple, because of left ventricular hypertrophy. There is no
proven treatment for this type of heart failure. The only
completed large randomized trial, CHARM-Preserved,
did not show a significant effect of candesartan on the
primary composite outcome although that treatment did
1422 McMurray: Chronic kidney disease in patients with cardiac disease
reduce the risk of admission to hospital for worsening
heart failure [41].
CORONARY HEART DISEASE: STABLE
ANGINA AND SECONDARY PREVENTION
AFTER MYOCARDIAL INFARCTION
As might be anticipated, the prevalence of chronic kid-
ney disease is less in patients with coronary heart disease
than in those with chronic heart failure [42–50]. Taking
age into account, chronic kidney disease seems to be more
common in patients with acute myocardial infarction, es-
pecially if associated with left ventricular systolic dysfunc-
tion or heart failure (about a third of such patients had
chronic kidney disease in two randomized trials (Table 1);
it is also more prevalent in unselected hospital cohorts
than in patients randomized in trials [42–50]. Retrospec-
tive analysis of trial cohorts and analyses of hospital co-
horts show, uniformly, that, as in chronic heart failure,
chronic kidney disease is a powerful independent predic-
tor of adverse cardiovascular outcome in patients with
coronary heart disease [42–50].
Six different classes of drug are of proven benefit in sec-
ondary prevention of myocardial infarction: beta block-
ers, antiplatelet agents, ACE inhibitors (and angiotensin
receptor blockers), statins, and aldosterone antagonists.
These agents are also thought to be “vasculoprotective”
in other subsets of patients with coronary heart disease
(and in arterial disease more generally), either by extrap-
olation or because they have also been studied in other
populations with atherosclerosis.
Beta blockers were the first class of drug shown to im-
prove prognosis after infarction [51]. No subset analysis
of the effect of beta blockers according to baseline renal
function in those trials has been published, although, on
the basis of the studies in heart failure mentioned above,
it would be reasonable to assume that the benefit of
beta blockers is preserved in patients with chronic kidney
disease.
Antiplatelet therapy has been studied in patients with
chronic kidney disease. A total of 2632 patients receiv-
ing hemodialysis were included in 14 trials of antiplatelet
therapy for the prevention of vascular access occlusion,
and antiplatelet therapy was associated with a statistically
significant 41% reduction in risk for a serious vascular
event in these patients [52]. There are reports that as-
pirin can prolong bleeding time markedly in patients with
advanced chronic kidney disease, although low dose as-
pirin (100 mg/day) did not cause excessive bleeding in the
first United Kingdom Heart and Renal Protection study
(UK-HARP-1) which enrolled patients who were pre-
dialysis (with a creatinine concentration of ≥150 lmol/L),
receiving dialysis (peritoneal or hemodialysis) or had
a functioning kidney transplant (any creatinine level)
[53, 54]. Clopidogrel is an alternative to aspirin which
does not cause gastric irritation (and can be used in addi-
tion to aspirin in high-risk patients with an acute coronary
syndrome and after coronary stenting) [55, 56]. No reduc-
tion in dose seems to be needed in chronic kidney disease.
In rare cases, use of clopidogrel has been associated with
thrombocytopenic purpura.
The next breakthrough in secondary prevention came
with ACE inhibitors in patients at high risk after myocar-
dial infarction because of left ventricular systolic dysfunc-
tion, heart failure, or both [57]. A retrospective analysis
of one of these landmark studies showed that the relative
benefits of captopril was preserved in patients with re-
duced renal function and this finding was supported and
extended by a similar analysis of the Heart Outcomes
Prevention Evaluation (HOPE) trial carried out in pa-
tients with cardiovascular disease or diabetes [58–61]. Of
course, because patients with chronic kidney disease were
at higher absolute risk in those studies and the relative
risk reduction with treatment was preserved, the absolute
benefit of ACE inhibition in patients with coronary heart
disease (CHD) and chronic kidney disease was large. Re-
cently, the Valsartan in Acute Myocardial Infarction Trial
(VALIANT) showed that valsartan 160 mg twice daily
was as effective as a proven dose of captopril and that its
efficacy, relative to captopril, was not altered by baseline
renal function [62].
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors or statins have been shown
to be remarkably effective in both the primary and sec-
ondary prevention of vascular events and these benefits
also seem to be preserved in patients with chronic kid-
ney disease [63, 64]. That has been most clearly shown
for pravastatin after acute myocardial infarction and in a
meta-analysis of primary and secondary prevention stud-
ies with that drug (Table 3) [63, 64]. Pravastatin may even
reduce the rate of decline in GFR in patients with coro-
nary heart disease (CHD) and chronic kidney disease
though this retrospective finding requires confirmation
in a prospective randomized trial [65]. Other large statin
trials excluded patients with a serum creatinine >150
lmol/L [the Collaborative Atorvastatin Diabetes Study
(CARDS)] or >200 lmol/L [the Anglo-Scandinavian
Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-
LLA with atorvastatin) and the Heart Protection Study
(HPS with simvastatin)] although, in two of these
(ASCOT and HPS) the benefit of statin treatment was
preserved in patients with a higher creatinine [66–68].
Patients with more advanced kidney failure were, how-
ever, generally excluded from the large statin trials and
in those patients the type of dyslipidemia and cardiovas-
cular events, as well as tolerability of a statin, may be
different than in individuals with less severe chronic kid-
ney disease. One study, the Assessment of Lescol in Renal
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Table 3. Effect of pravastatin use on incidence of cardiovascular events in participants with chronic renal insufficiency, as defined by creatinine
clearance of 75 mL/min or less in the Cholesterol And Recurrent Events Trial (CARE)
Participants in Participants in Adjusted HR with
Event the placebo group the pravastatin group pravastatin (95% CI) P value
Death from coronary heart disease 126 (14.5) 89 (10.5) 0.72 (0.55 to 0.95) 0.02
or nonfatal myocardial infarction
Major coronary event 294 (27.0) 171 (20.8) 0.72 (0.59 to 0.88) 0.001
Total mortality 111 (12.8) 86 (10.2) 0.81 (0.61 to 1.08) 0.14
Fatal myocardial infarction 90 (10.4) 65 (7.7) 0.73 (0.52 to 1.01) 0.06
or confirmed nonfatal myocardial infarction
Coronary artery bypass grafting 153 (17.6) 10.5 (12.4) 0.65 (0.50 to 0.83) 0.001
or percutaneous transluminal coronary angioplasty
Unstable angina 142 (16.4) 133 (15.8) 0.93 (0.73 to 1.18) >0.2
Stroke 46 (5.3) 29 (3.4) 0.62 (0.89 to 1.00) 0.051
Adapted from [64].
Transplantation study (ALERT), showed that fluvastatin
80 mg/day given for a mean of 5.1 years was safe in pa-
tients with a renal transplant and a total cholesterol con-
centration of between 4.0 and 9.0 mmol/L [69]. Although
fluvastatin did not reduce the risk of the primary com-
posite end point (cardiac death, nonfatal myocardial in-
farction, or coronary revascularization procedure) signif-
icantly, it did reduce the risk of myocardial infarction and
cardiac death. That observation contrasts, strikingly, with
the findings of the Deutsche Diabetes Dialyse Studie (the
“4D Study”) in which 1255 patients with type 2 diabetes
on hemodialysis were treated with 20 mg atorvastatin or
matching placebo for a median of 4 years. Many patients
had established cardiovascular disease. The median re-
duction in low-density lipoprotein (LDL) was 41% and
that was maintained over the study period. There was only
an 8% risk reduction with atorvastatin in the primary end
point (a composite of cardiac death, nonfatal myocardial
infarction, or stroke), which was not statistically signifi-
cant [Christoph Wanner for the 4D Study investigators,
American Society Nephrology, 37th Annual Meeting, St.
Louis, MO, October 2004]. Why these trials gave different
answers is uncertain. Two further large trials of a statin
in chronic kidney disease are underway. The Assessment
of Survival and Cardiovascular Events Trial (AURORA)
is assessing the effects of rosuvastatin on cardiovascular
morbidity and mortality in about 2700 patients on chronic
hemodialysis [70]. The Study of Heart and Renal Protec-
tion (SHARP) is evaluating the effect of simvastatin and
the cholesterol-absorption inhibitor ezetimibe in approx-
imately 9000 patients with kidney failure, about 6000 of
whom will be on predialysis, and 3000 on dialysis [71].
Unlike the overwhelming evidence of efficacy and
safety of statins in patients with coronary heart disease
there is only modest evidence of improvement in clin-
ical outcomes with other lipid-modifying agents. One
drug with such evidence is gemfibrozil. Although the
Veterans Affairs High-Density Lipoprotein Intervention
Trial (VA-HIT) excluded patients with a serum creati-
nine ≥177 lmol/L, it did enroll 1046 out of 2505 patients
with a creatinine clearance of ≤75 mL/min estimated
using the Cockcroft-Gault equation (39% had a GFR
≤60 mL/min). The benefits of gemfibrozil were preserved
in these higher-risk patients. Treatment with gemfibrozil
was, however, associated with a significantly higher inci-
dence of a sustained increase in serum creatinine concen-
tration (5.9%) than placebo (2.8%) [72].
As in chronic heart failure, aldosterone blockade has
been shown to reduce mortality and morbidity in patients
with left ventricular systolic dysfunction after acute my-
ocardial infarction and either clinical evidence of heart
failure or diabetes mellitus. In the Eplerenone Post-Acute
Myocardial Infarction Heart Failure Efficacy and Sur-
vival Study (EPHESUS) this treatment reduced the risk
of death by 15% when added to all of the above sec-
ondary prevention treatments [73]. Although patients
with a serum creatinine concentration of >2.5 mg/dL (221
lmol/L) were excluded, probably around a third still had
chronic kidney disease. Interestingly, when the effect of
treatment was examined according to baseline creatinine
concentration (above and below median of 1.1 mg/dL),
the effect of eplerenone on all-cause mortality appeared
to be significantly less in those with a higher creatinine
(interaction P value 0.03); however, no interaction was
apparent for the composite outcome of death or hospi-
talization due to a cardiovascular cause. Unsurprisingly,
creatinine and potassium increased more on eplerenone
than on placebo. Current product labeling in Europe ad-
vises that eplerenone is not used in patients with a GFR
of <50 mL/min.
Both percutaneous and surgical coronary revascular-
ization are indicated to relieve symptoms that persist de-
spite medical antianginal treatment; surgical revascular-
ization may also improve survival in subsets of patients
with angina and coronary stenoses which compromise
blood flow a large volume of myocardium (e.g., three-
vessel or left main stenosis). Detailed discussion of this
complex subject is beyond the scope of this review but it
is dealt with well elsewhere; drug eluting stents and “off-
pump” coronary bypass grafting are new developments
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that may increase the success of each type of revascu-
larization [74–79]. The management of acute coronary
syndromes is also complicated, where even the use of ra-
diographic contrast for diagnostic angiography has to be
considered carefully [74–79].
Despite recognition of the particular risk faced by pa-
tients with cardiovascular disease and chronic kidney dis-
ease and, as reviewed here, evidence that treatment ef-
ficacy is maintained, as well as authoritative guidelines
on the use of these therapies, there are considerable data
to show that patients of this type are undertreated [10,
80–82].
CONCLUSION
Chronic kidney disease is very common in patients with
cardiovascular disease and increases their risk of fatal and
nonfatal cardiovascular events. There are many effective
treatments which reduce these risks and most seem to
be equally effective in patients with chronic kidney dis-
ease, although most trials randomized very few patients
with severe chronic kidney disease. Recently, clinical
trials which are specifically testing treatments to reduce
cardiovascular risk in patients with ESRD have been
initiated and should fill an important gap in evidence-
based treatment of cardiovascular risk in chronic kidney
disease.
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